Cyanine3 amine
Cat. # | Quantity | Price | Lead time | Buy this product |
---|---|---|---|---|
110C0 | 1 mg | $125 | in stock | |
210C0 | 5 mg | $260 | in stock | |
410C0 | 25 mg | $510 | in stock | |
510C0 | 50 mg | $895 | in stock | |
610C0 | 100 mg | $1490 | in stock |
Cyanine3 amine is a functionalized cyanine dye containing a free amino group. Cyanine3 is an analog of Cy3®.
Amino group of this reagent can be conjugated with reactive groups such as NHS esters, carboxy groups (after carbodiimide activation), and epoxides.
The amino dye is supplied in salt form, and possesses some aqueous solubility.
Cyanine3 absorption and emission spectra
Customers also purchased with this product
Cyanine5.5 carboxylic acid
Cyanine5.5 dye, free acid form, unactivated. The dye can be considered non-reactive for most applications.sulfo-Cyanine7 amine
NIR dye amine, sulfonated derivative of Cyanine7 dye, for the modification via enzymatical transamination.BDP® TR hydrazide
BDP TR hydrazide for the labeling of carbonyl compounds with BDP TR, a borondipyrromethene matching ROX channel.General properties
Appearance: | red powder |
Molecular weight: | 627.73 |
CAS number: | 2247688-56-6 |
Molecular formula: | C36H52Cl2N4O |
IUPAC name: | 3H-Indolium, 1-[6-[(6-aminohexyl)amino]-6-oxohexyl]-2-[3-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-1-propen-1-yl]-3,3-dimethyl-, chloride, hydrochloride (1:1:1) |
Solubility: | moderate solubility in water, good in polar organic solvents (DMF, DMSO, alcohols) |
Quality control: | NMR 1H, HPLC-MS (95%) |
Storage conditions: | Storage: 24 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Avoid prolonged exposure to light. Desiccate. |
MSDS: | Download |
Product specifications |
Spectral properties
Excitation/absorption maximum, nm: | 555 |
ε, L⋅mol−1⋅cm−1: | 150000 |
Emission maximum, nm: | 570 |
Fluorescence quantum yield: | 0.31 |
CF260: | 0.04 |
CF280: | 0.09 |
Product citations
- Kovshova, T.; Malinovskaya, J.; Kotova, J.; Gorshkova, M.; Vanchugova, L.; Osipova, N.; Melnikov, P.; Vadekhina, V.; Nikitin, A.; Ermolenko, Y.; Gelperina, S. Core–Shell PLGA Nanoparticles: In Vitro Evaluation of System Integrity. Biomolecules, 2024, 14(12), 1601. doi: 10.3390/biom14121601
- Gorshkova, M.; Vanchugova, L.; Osipova, N.; Nikitin, A.; Kotova, J.; Kovalenko, E.; Ermolenko, Y.; Malinovskaya, J.; Kovshova, T.; Gelperina, S. Hybrid DIVEMA/PLGA nanoparticles as the potential drug delivery system. Research Square, 2024, preprint. doi: 10.21203/rs.3.rs-4594368/v1
- Lee, J.-R.; Sim, W.-S.; Park, H.-J.; Park, B.-W.; Joung, Y. K. Targeted Delivery of Apoptotic Cell-Derived Nanovesicles Prevents Cardiac Remodeling and Attenuates Cardiac Function Exacerbation. Advanced Functional Materials, 2023, 33(23), 2210864. doi: 10.1002/adfm.202210864
- Ruan, Z.; Li, S.; Grigoropoulos, A.; Amiri, H.; Hilburg, S. L.; Chen, H.; Jayapurna, I.; Jiang, T.; Gu, Z.; Alexander-Katz, A.; Bustamante, C.; Huang, H.; Xu, T. Population-Based Heteropolymer Design to Mimic Protein Mixtures. Nature, 2023, 615(7951), 251–258. doi: 10.1038/s41586-022-05675-0
Cy® is a trademark of GE Healthcare.
Your item has been added.
View your
cart
or
proceed to checkout
The count of items is incorrect.